navitoclax
Overview
Navitoclax (ABT-263) is an orally bioavailable BH3-mimetic that inhibits BCL-2, BCL-XL, and BCL-W anti-apoptotic proteins, promoting apoptosis in cancer cells that depend on these survival signals. It has been investigated as a senolytic agent to clear senescent cells.
Evidence in the corpus
- Tested as a senolytic agent in KRASG12C-amplified colorectal cancer cells that entered oncogene-induced senescence after sotorasib + cetuximab withdrawal; navitoclax did NOT show selective activity in the senescent (drug-off) condition, in contrast to the mTOR inhibitor AZD8055 which did show selective cytotoxicity PMID:36355783
Resistance mechanisms
Cancer types (linked)
- COADREAD — tested as senolytic in KRASG12C-amplified, drug-resistant colorectal cancer models
Sources
This page was processed by crosslinker on 2026-05-06.